SG Americas Securities LLC lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 95.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,065 shares of the company’s stock after selling 24,741 shares during the period. SG Americas Securities LLC’s holdings in IDEXX Laboratories were worth $172,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. State of Wisconsin Investment Board raised its stake in shares of IDEXX Laboratories by 35.1% in the 2nd quarter. State of Wisconsin Investment Board now owns 109,103 shares of the company’s stock worth $17,611,000 after buying an additional 28,320 shares in the last quarter. LMR Partners LLP bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth $3,244,000. Dupont Capital Management Corp bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth $2,322,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in shares of IDEXX Laboratories by 176.0% in the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 95,432 shares of the company’s stock worth $15,405,000 after buying an additional 60,859 shares in the last quarter. Finally, Rational Advisors LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth $743,000. 87.64% of the stock is currently owned by institutional investors.

IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at 155.76 on Friday. IDEXX Laboratories, Inc. has a one year low of $102.45 and a one year high of $173.01. The company has a 50 day moving average price of $154.86 and a 200-day moving average price of $159.27. The firm has a market capitalization of $13.59 billion, a PE ratio of 53.58 and a beta of 0.49.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.10. The company had revenue of $508.90 million for the quarter, compared to the consensus estimate of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.74 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post $3.18 EPS for the current year.

In other news, Chairman Jonathan W. Ayers sold 13,000 shares of the stock in a transaction on Monday, August 28th. The stock was sold at an average price of $150.79, for a total value of $1,960,270.00. Following the transaction, the chairman now owns 1,044,034 shares of the company’s stock, valued at approximately $157,429,886.86. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Jonathan W. Ayers sold 58,000 shares of the stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $155.00, for a total value of $8,990,000.00. Following the completion of the transaction, the chairman now directly owns 1,043,034 shares in the company, valued at approximately $161,670,270. The disclosure for this sale can be found here. In the last three months, insiders sold 151,734 shares of company stock worth $23,436,626. 2.77% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “SG Americas Securities LLC Reduces Stake in IDEXX Laboratories, Inc. (IDXX)” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/22/sg-americas-securities-llc-reduces-stake-in-idexx-laboratories-inc-idxx.html.

A number of analysts have recently commented on the company. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $182.00 price objective on the stock in a research note on Wednesday, June 28th. Aegis assumed coverage on IDEXX Laboratories in a research note on Wednesday, May 31st. They issued a “sell” rating and a $118.00 price objective on the stock. They noted that the move was a valuation call. Bank of America Corporation raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective on the stock in a research note on Wednesday, August 23rd. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 5th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research note on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. IDEXX Laboratories currently has an average rating of “Hold” and a consensus target price of $174.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.